文献速递造血干细胞移植与细胞治疗

全身补体激活影响异基因造血细胞移植后的结局:一项法国前瞻性多中心试验

Systemic complement activation influences outcomes after allogeneic hematopoietic cell transplantation: A prospective French multicenter trial.
PubMed 文献 · Am J Hematol · 2023-07-22

该前瞻性多中心试验对85例接受清髓性预处理(MAC)的异基因造血细胞移植(allo-HSCT)患者进行12周系列补体蛋白、调节蛋白及CH50活性监测,26例呈现经典型/凝集素途径「激活」补体谱。补体激活与更高的非复发死亡率、更差总生存及急性GVHD、血栓性微血管病、毛细血管渗漏综合征、植入后细菌感染和EBV再激活发生率相关。

要点

  • 85例MAC方案allo-HSCT患者中26例出现经典型/凝集素途径补体激活谱。
  • 补体激活与non-relapse mortality(HR 3.69)和总生存更差(HR 2.72)相关。
  • 补体激活与胃肠道GVHD(HR 36.8)、血栓性微血管病(HR 8.58)等相关。

核心结论

  • MAC方案后经典型/凝集素途径补体激活与不良移植结局相关,为移植后使用补体抑制治疗提供依据。

研究设计与样本

  • 前瞻性多中心试验(NCT01520623),纳入85例接受MAC方案治疗各种血液系统恶性肿瘤的allo-HSCT患者,移植后12周内系列检测补体蛋白、调节蛋白及CH50活性。

主要发现

  • 85例中26例呈现经典型/凝集素途径「激活」补体谱,定义为移植后C3/C4及CH50活性下降。
  • 时间依赖Cox回归显示补体激活与non-relapse mortality升高相关(HR 3.69,95%CI 1.55-8.78,p=.003)。
  • 补体激活与总生存更差相关(HR 2.72,95%CI 1.37-5.39,p=.004)。
  • 补体激活与II-IV级急性GVHD尤其胃肠道GVHD发生率升高相关(HR 36.8,95%CI 12.4-109.1,p<.001)。
  • 补体激活与血栓性微血管病(HR 8.58,95%CI 2.16-34.08,p=.0022)、毛细血管漏综合征(HR 7.36,95%CI 2.51-21.66,p=.00028)、植入后细菌感染(HR 2.37,95%CI 1.22-4.63,p=.0108)及EBV再激活(HR 3.33,95%CI 1.31-8.45,p=.0112)发生率升高相关。

关键数值与推荐

  • 补体「激活」谱定义为移植后C3/C4及CH50活性下降。
  • 免疫染色显示胃肠道GVHD病变内皮细胞上C1q、C3d、C4d及C5b9沉积与GVHD组织学分级相关。

临床怎么用

  • 作者认为这些发现为移植后场景使用补体抑制治疗提供了依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Complement activation has shown a role in murine models of graft-versus-host disease (GVHD) and in endothelial complications after allogeneic hematopoietic cell transplantation (allo-HSCT). However, its impact on post-transplant outcomes has not been so far fully elucidated. Here, we conducted a prospective multicentric trial (NCT01520623) performing serial measurements of complement proteins, regulators, and CH50 activity for 12 weeks after allo-HSCT in 85 patients receiving a myeloablative conditioning (MAC) regimen for various hematological malignancies. Twenty-six out of 85 patients showed an "activated" complement profile through the classical/lectin pathway, defined as a post-transplant decline of C3/C4 and CH50 activity. Time-dependent Cox regression models demonstrated that complement activation within the first weeks after allo-HSCT was associated with increased non-relapse mortality (hazard ratio [HR]: 3.69, 95% confident interval [CI]: 1.55-8.78, p = .003) and poorer overall survival (HR: 2.72, 95% CI: 1.37-5.39, p = .004) due to increased incidence of grade II-IV acute GVHD and in particular gastrointestinal (GI) GVHD (HR: 36.8, 95% CI: 12.4-109.1, p < .001), higher incidences of thrombotic microangiopathy (HR: 8.58, 95% CI: 2.16-34.08, p = .0022), capillary leak syndrome (HR: 7.36, 95% CI: 2.51-21.66, p = .00028), post-engraftment bacterial infections (HR: 2.37, 95% CI: 1.22-4.63, p = .0108), and EBV reactivation (HR: 3.33, 95% CI: 1.31-8.45, p = .0112). Through specific immune staining, we showed the correlation of deposition of C1q, C3d, C4d, and of C5b9 components on endothelial cells in GI GVHD lesions with the histological grade of GVHD. Altogether these findings define the epidemiology and the clinical impact of complement classical/lectin pathway activation after MAC regimens and provide a rational for the use of complement inhibitory therapeutics in a post-allo-HSCT setting.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Notarantonio AB, D'aveni-Piney M, Pagliuca S, et al. Systemic complement activation influences outcomes after allogeneic hematopoietic cell transplantation: A prospective French multicenter trial. Am J Hematol. 2023. PMID: 37483161. doi:10.1002/ajh.27030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。